SYNDROME VIRUS AND USES THEREOF

CROSS-REFERENCE TO RELATED APPLICATION

[0001] This application claims benefit of and priority to US Provisional Patent Application Serial No. 63/321,209, entitled “ANTIBODY FOR PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROMVE VIRUS (PRRSV)”, filed on March 18, 2022. The contents of the above-mentioned application are hereby incorporated by reference herein for all purposes.

REFERENCE TO SEQUENCE LISTING

[0002] Accompanying this application is a sequence listing in an XML file named “2022A-154596-SequenceListmg.xml”, created March 16, 2023, and having a size of 13,772 bytes. The sequence listing is hereby fully incorporated by reference herein.

FIELD

[0003] The present disclosure generally relates to an antibody or an antigen-binding fragment and, more specifically, relates to an antibody or an antigen-binding fragment for recognizing Porcine Reproductive and Respiratory' Syndrome Virus and use of the same.

BACKGROUND

[0004] Porcine reproductive and respiratory syndrome (PRRS) is viewed by many as the most important disease currently affecting the pig industry worldwide. Porcine reproductive and respiratory syndrome causes severe reproduction losses, is associated with increased mortality due to secondary infections, and is linked to reduced feed conversion and average daily weight gain. Unfortunately, control of the virus that causes PRRS has proven to be difficult.

[0005] PRRSV is an enveloped single-stranded RNA virus classified in the family Arteriviridae (Cavanaugh, 1997). The virus causes a widespread disease of swine that was first described as a ‘mystery swine disease’ in the USA in 1987 (Hill, 1990). The disease manifests as respiratory illness in all age groups of swine leading to death in some younger pigs and severe reproductive problems in breeding-age females.

[0006] PRRSV infection is widespread on most pig farms in the world. PRRSV has been found to cause low survival rates and low feed conversion rates (FCRs) of infected pigs and results in great economic losses in pig farming. There are some PRRSV test kits for commercial use. However, the PRRSV test kits that are commercially available ty pically involve long testing times and involve a need to prepare more reagents. Therefore, it is important to develop PRRSV test kits that can detect PRRSV more easily and quickly.

SUMMARY

[0007] The present disclosure is directed to an antibody or an antigen-binding fragment and, more specifically, to an antibody or an antigen-binding fragment for recognizing Porcine Reproductive and Respiratory Syndrome Virus and use of the same.

[0008] According to a first aspect of the present disclosure, an antibody or antigen-binding fragment thereof binding to PRRSV is provided, which includes: a heavy chain variable domain including a heavy chain complementarity-determining region 1 (CDR-H1) containing a sequence of SEQ ID NO: 1 , a CDR-H2 containing a sequence of SEQ ID NO: 2, and a CDR-H3 containing a sequence of SEQ ID NO: 3; and a light chain variable domain including a light chain complementarity-determining region 1 (CDR-L1) including a sequence of SEQ ID NO: 4, a CDR-L2 containing a sequence of Leu- Ala-Ser, and a CDR-L3 containing a sequence of SEQ ID NO: 5.

[0009] In an implementation of the first aspect of the present disclosure, the heavy chain variable domain further includes a sequence of SEQ ID NO: 6.

[0010] In another implementation of the first aspect of the present disclosure, the light chain variable domain further includes a sequence of SEQ ID NO: 7.

[0011] According to a second aspect of the present disclosure, an isolated nucleic acid encoding the antibody or antigen-binding fragment thereof of the first aspect of the present disclosure is provided, the isolated nucleic acid encoding the antibody or antigen-binding fragment thereof comprises a first fragment encoding a heavy chain variable domain and a second fragment encoding a light chain variable domain.

[0012] In an implementation of the second aspect of the present disclosure, the first fragment encoding the heavy chain variable domain further includes a sequence of SEQ ID NO: 8. [0013] In an implementation of the first aspect of the present disclosure, the second fragment encoding the light chain variable domain further includes a sequence of SEQ ID NO: 9. [0014] According to a third aspect of the present disclosure, a vector including the isolated nucleic acid of the second aspect of the present disclosure is provided.

[0015] According to a fourth aspect of the present disclosure, a host cell including the vector of the third aspect of the present disclosure is provided.

[0016] According to a fifth aspect of the present disclosure, a method for producing an antibody or antigen-binding fragment thereof binding to PRRSV is provided, which includes: (a) culturing the host cell of the fourth aspect of the present disclosure under conditions suitable for expressing the antibody or antigen-binding fragment thereof; and (b) recovering the antibody or antigen-binding fragment thereof.

[0017] In an implementation of the fifth aspect of the present disclosure, the heavy chain vanable domain further includes a sequence of SEQ ID NO: 6.

[0018] In another implementation of the fifth aspect of the present disclosure, the light chain variable domain further includes a sequence of SEQ ID NO: 7.

[0019] According to a sixth aspect of the present disclosure, a method for detecting PRRSV is provided, and the method includes contacting a sample with the antibody or antigen-binding fragment thereof of the first aspect of the present disclosure.

[0020] In another implementation of the sixth aspect of the present disclosure, the heavy chain variable domain further includes a sequence of SEQ ID NO: 6.

[0021] In another implementation of the sixth aspect of the present disclosure, the light chain variable domain further includes a sequence of SEQ ID NO: 7.

[0022] According to a seventh aspect of the present disclosure, a biological field-effect transistor (Bio-FET) is provided, which includes: a transistor region; and a detecting region, wherein the detecting region includes a detecting surface that is functionalized with an antibody or antigen-binding fragment thereof binding to PRRSV, wherein the antibody or antigen-binding fragment thereof includes: a heavy chain variable domain including a heavy chain complementarity-determining region 1 (CDR-H1) containing a sequence of SEQ ID NO: 1, a CDR-H2 containing a sequence of SEQ ID NO: 2, and a CDR-H3 containing a sequence of SEQ ID NO: 3; and a light chain variable domain including a light chain complementarity-determining region 1 (CDR-L1) containing a sequence of SEQ ID NO: 4, a CDR-L2 containing a sequence of Leu- Ala-Ser, and a CDR-L3 containing a sequence of SEQ ID NO: 5.

[0023] In another implementation of the seventh aspect of the present disclosure, the heavy chain variable domain further includes a sequence of SEQ ID NO: 6.

[0024] In another implementation of the seventh aspect of the present disclosure, the light chain variable domain further includes a sequence of SEQ ID NO: 7.

[0025] According to an eighth aspect of the present disclosure, a method for detecting PRRSV by using a biological field-effect transistor (Bio-FET) is provided, and the method includes: (a) contacting a sample with an antibody or antigen-binding fragment thereof immobilized on a detecting surface of the Bio-FET, wherein the antibody or antigen-binding fragment thereof includes: a heavy chain variable domain including a heavy chain complementarity-determining region 1 (CDR-H1) containing a sequence of SEQ ID NO: 1, a CDR-H2 containing a sequence of SEQ ID NO: 2, and a CDR-H3 containing a sequence of SEQ ID NO: 3; and a light chain variable domain including a CDR-L1 containing a sequence of SEQ ID NO: 4, a CDR-L2 containing a sequence of Leu-Ala-Ser, and a CDR-L3 containing a sequence of SEQ ID NO: 5, wherein the antibody or antigen-binding fragment thereof binds to PRRSV; and (b) analyzing an electric signal obtained from the Bio-FET.

[0026] In another implementation of the eighth aspect of the present disclosure, the heavy chain variable domain further includes a sequence of SEQ ID NO: 6.

[0027] In another implementation of the eighth aspect of the present disclosure, the light chain variable domain further includes a sequence of SEQ ID NO:7.

[0028] According to a ninth aspect of the present disclosure, a composition for detecting Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) is provided, wherein the composition for detecting PRRSV comprises an antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises: a heavy chain variable domain comprising a heavy chain complementarity -determining region 1 (CDR-H1) containing a sequence of SEQ ID NO: 1, a CDR-H2 containing a sequence of SEQ ID NO: 2, and a CDR-H3 containing a sequence of SEQ ID NO: 3; and a light chain variable domain, comprising a light chain complementarity-determining region 1 (CDR-L1) containing a sequence of SEQ ID NO: 4, a CDR-L2 containing a sequence of Leu- Ala-Ser, and a CDR-L3 containing a sequence of SEQ ID NO: 5.

[0029] In another implementation of the ninth aspect of the present disclosure, the heavy chain variable domain further includes a sequence of SEQ ID NO: 6.

[0030] In another implementation of the ninth aspect of the present disclosure, the light chain variable domain further includes a sequence of SEQ ID NO: 7.

[0031] In another implementation of the ninth aspect of the present disclosure, the composition for detecting PRRSV may be a biochip device, or a detection kit includes the biochip device (e.g., Bio-FET), or a detection kit using for western blotting, chemiluminescence microparticle immunoassay (CMIA), chemiluminescence immunoassay (CLIA), lateral flow immunoassay (LF1A), or Enzyme-linked immunosorbent assay (ELISA).

[0032] According to a tenth aspect of the present invention, a use of an antibody or antigen-binding fragment thereof for the preparation of a composition for detecting Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) in a subject or a sample from the subject is provided, wherein the antibody or antigen-binding fragment thereof comprises: a heavy chain variable domain comprising a heavy chain complementarity-determining region 1 (CDR-H1) containing a sequence of SEQ ID NO: 1, a CDR-H2 containing a sequence of SEQ

ID NO: 2, and a CDR-H3 containing a sequence of SEQ ID NO: 3; and a light chain variable domain comprising a light chain complementarity-determining region 1 (CDR-L1) containing a sequence of SEQ ID NO: 4, a CDR-L2 containing a sequence of Leu-Ala-Ser, and a CDR-L3 containing a sequence of SEQ ID NO: 5; and the subject is swine.

[0033] In another implementation of the tenth aspect of the present disclosure, the heavy chain variable domain further includes a sequence of SEQ ID NO: 6.

[0034] In another implementation of the tenth aspect of the present disclosure, the light chain variable domain further includes a sequence of SEQ ID NO: 7.

[0035] In another implementation of the tenth aspect of the present disclosure, the subject is swine.

[0036] According to an eleventh aspect of the present invention, an use of a biological field-effect transistor (Bio-FET) for the preparation of a composition for detecting Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) in a subject or a sample from the subject is provided, wherein the Bio-FET comprises an antibody or antigen-binding fragment that comprises: a heavy chain variable domain comprising a heavy chain complementarity-determining region 1 (CDR-H1) containing a sequence of SEQ ID NO: 1, a CDR-H2 containing a sequence of SEQ ID NO: 2, and a CDR-H3 containing a sequence of SEQ ID NO: 3; and a light chain variable domain comprising a light chain complementarity-determining region 1 (CDR-L1) containing a sequence of SEQ ID NO: 4, a

CDR-L2 containing a sequence of Leu- Ala-Ser, and a CDR-L3 containing a sequence of SEQ ID NO: 5.

[0037] Tn another implementation of the eleventh aspect of the present disclosure, the subject is swine.

[0038] In another implementation of the eleventh aspect of the present disclosure, the heavy chain variable domain further includes a sequence of SEQ ID NO: 6.

[0039] In another implementation of the eleventh aspect of the present disclosure, the light chain variable domain further includes a sequence of SEQ ID NO: 7.

[0040] In another implementation of the eleventh aspect of the present disclosure, the antibody or antigen-binding fragment thereof is immobilized on a detecting surface of the Bio-FET.

[0041] With application to the aforementioned antibody or antigen-binding fragment thereof, the antibody or antigen-binding fragment thereof specifically recognizes PRRSV with high sensitivity, leading to excellent detection of PRRSV, thereby being applied to various uses, for example, western blotting, chemiluminescence microparticle immunoassay (CMIA), chemiluminescence immunoassay (CLIA), lateral flow immunoassay (LFIA) or Enzyme-linked immunosorbent assay (ELISA), or using Biochip devices (e g., Bio-FET).

BRIEF DESCRIPTION OF THE DRAWINGS [0042] The disclosure can be more fully understood by reading the following detailed description of the embodiment, with reference made to the accompanying drawings as follows.

[0043] FIG. 1 A illustrates the sensitivity of anti-PRRSV antibody 477 (denoted as no. 477) to PRRSV (denoted as 763-P8) or pseudorabies virus (denoted as S1462-P7-PRV) when being applied on Bio-FET.

[0044] FIG. IB illustrates the sensitivity of anti-PRRSV antibody 277 (denoted as no. 277) to PRRSV (denoted as 763-P8) or pseudorabies virus (denoted as S1462-P7-PRV) when being applied on Bio-FET.

[0045] FIG. 2 illustrates the cross-reactivity of anti-PRRSV antibody 477 (denoted as no. 477) to PRRSV (denoted as 763-P8), pseudorabies virus (denoted as S1462-P7-PRV), porcine coronavirus (denoted as FCOV-P7), or porcine circovirus type 2 (denoted as 110-873 S) when being applied on Bio-FET.

DETAILED DESCRIPTION

[0046] The detailed description provided below in connection with the appended drawings is intended as a description of the present examples and is not intended to represent the only forms in which the present example may be constructed or utilized. The description sets forth the functions of the examples and the sequence of steps for constructing and operating the examples. However, the same or equivalent functions and sequences may be accomplished by different examples. [0047] DEFINITIONS

[0048] For convenience, certain terms employed in the specification, examples and appended claims are collected here Unless otherwise defined herein, scientific, and technical terminologies employed in the present disclosure shall have the meanings that are commonly understood and used by one of ordinary skill in the art. Also, unless otherwise required by context, it will be understood that singular terms shall include plural forms of the same and plural terms shall include the singular. Specifically, as used herein and in the claims, the singular forms “a” and “an” include the plural reference unless the context clearly indicates otherwise. Also, as used herein and in the claims, the terms “at least one” and “one or more” have the same meaning and include one, two, three, or more.

[0049] The terms "first", "second", and "third" in the description of the present invention and the above-mentioned drawings are used to distinguish different objects, rather than to describe a specific order.

[0050] The term “antibody” is used in the broadest sense and specifically covers monoclonal antibodies (including full-length monoclonal antibodies), polyclonal antibodies, multi-specific antibodies (e.g., bi-specific antibodies), and antibody fragments so long as they exhibit the desired biological activity. “Antibody fragments” include a portion of a full-length antibody, generally the antigen binding or variable region thereof. Examples of antibody fragments include Fab, Fab', F(ab')2, reduced IgG (rlgG), and Fv fragments; diabodies; linear antibodies; single-chain antibody molecules; and multi-specific antibodies formed from antibody fragments. [0051] “Antibody fragments” include only a portion of an intact antibody, wherein the portion retains at least one, and as many as most or all, of the functions normally associated with that portion when present in an intact antibody. In one embodiment, an antibody fragment includes an antigen-binding site of the intact antibody and thus retains the ability to bind the antigen. In another embodiment, an antibody fragment, for example, one that includes the Fc region, retains at least one of the biological functions normally associated with the Fc region when present in an intact antibody, antibody half-life modulation, antibody-dependent cell-mediated cytotoxicity (ADCC) function, and complement binding. In one embodiment, an antibody fragment is a monovalent antibody that has an in vivo half-life substantially similar to that of an intact antibody. For example, such an antibody fragment may include an antigen-binding arm linked to an Fc sequence capable of conferring in vivo stability to the fragment. The antibody fragment in the present disclosure may exist in a variety of forms including, for example, variable fragment (Fv), single-chain variable fragment (scFv), antigen-binding fragment (Fab), reduced IgG (rlgG), and divalent antibody fragment [F(ab’)2], as well as single-chain antibodies. [0052] The “variable region” or “variable domain” of an antibody refers to the amino-terminal domains of the heavy or light chain of the antibody These domains are generally the most variable parts of an antibody and contain the antigen-binding sites

[0053] The term “variable” refers to the fact that certain portions of the variable domains differ extensively in sequence among antibodies and are used in the binding and specificity of each particular antibody for its particular antigen. However, the variability' is not evenly distributed throughout the variable domains of antibodies but is concentrated in three segments called complementarity-determining regions (CDRs) or hypervariable regions both in the light-chain and the heavy-chain variable domains. The more highly conserved portions of variable domains are called the framework (FR). The variable domains of native heavy and light chains each include four FR regions, largely adopting a beta-sheet configuration, connected by three CDRs, which form loops connecting, and in some cases forming part of, the beta-sheet structure. The CDRs in each chain are held together in close proximity by the FR regions and, with the CDRs from the other chain, contribute to the formation of the antigen-binding site of antibodies (see Kabat et al.. Sequences of Proteins of Immunological Interest, Fifth Edition, National Institute of Health, Bethesda, Md. (1991)). The constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such as the participation of the antibody in antibody-dependent cellular toxicity. [0054] The term “complementarity-determining region” (CDR) used herein refers to the hypervariable region of an antibody molecule that forms a surface complementary to the 3-dimensional surface of a bound antigen. Proceeding from N-terminus to C -terminus, each of the antibody heavy and light chains includes three CDRs (CDR1 , CDR2, and CDR3). Therefore, the antibody includes a total of six CDRs that include three CDRs from the variable region of a heavy chain and three CDRs from the variable region of a light chain.

[0055] As discussed herein, minor variations in the amino acid sequences of antibodies are contemplated as being encompassed by the presently disclosed and claimed inventive concept(s), providing that the variations in the amino acid sequence maintain at least 85% sequence identity. Antibodies of the present disclosure may be modified specifically to alter a feature of the peptide unrelated to its physiological activity. For example, certain amino acids can be changed and/or deleted without affecting the physiological activity of the antibody in this study (e.g., its ability to detect PRRSV). In particular, conservative ammo acid replacements are contemplated. For example, it is reasonable to expect that an isolated replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, a threonine with a serine, or a similar replacement of an amino acid with a structurally related amino acid will not have a major effect on the binding or properties of the resulting molecule, especially if the replacement does not involve an amino acid within a framework site. Whether an amino acid change results in a functional peptide can readily be determined by assaying the specific activity of the peptide derivative. Fragments or analogs of antibodies can be readily prepared by those of ordinary skill in the art. Preferred amino- and carboxyl-termini of fragments or analogs occur near boundaries of functional domains.

[0056] Anti-PRRSV antibody 477 is denoted as antibody 477, no. 477, or 477; anti-PRRSV antibody 277 is denoted as antibody 277, no. 277, or 277.

[0057] (i) Antibody preparation

[0058] According to certain embodiments of the present disclosure, the antibody is derived from a hybridoma clone 477, designated as antibody 477. In these embodiments, the CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, CDR-L3, CDR VH (heavy chain variable domain) and CDR-VL (light chain variable domain) of antibody 477 includes the amino acid sequences shown in the sequence listing.

[0059] The anti-PRRSV antibody of the present disclosure may be produced by a production method as described below. Specifically, for example, nonhuman mammals such as antibody-producing mice are immunized with PRRSV, a part of PRRSV, or a conjugate of the part of PRRSV and an appropriate carrier substance (e.g., bovine serum albumin) for enhancing antigenicity together with, if necessary, an immuno-augmenting agent (e.g., Freund's complete or incomplete adjuvant). As PRRSV, both natural PRRSV and recombinant PRRSV may be used. Alternatively, immunization may be performed by introducing a gene encoding PRRSV and then administering animal cells that overexpress PRRSV on their cell surfaces. A monoclonal antibody may be obtained by fusing antibody -producing cells obtained from immunized animals to myeloma cells incapable of producing any autoantibody, culturing the thus-obtained hybridomas, and then selecting clones that produce the monoclonal antibody showing a specific affinity for an antigen used for immunization.

[0060] Alternatively, to certain embodiments of the present disclosure, the present antibody (e.g., antibody 477) may be produced by DNA cloning. DNA encoding the present antibody may be easily isolated and sequenced by use of conventional procedures, such as using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the antibody. The DNA sequences encoding the CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 of the antibody 477 used herein are also shown in the sequence listing provided below. Once isolated, the DNA may be placed into expression vectors which are then transfected into host cells and cultured under conditions suitable for expression. The term “expression vector” refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. In one embodiment, the vector used herein is an expression vector and maybe a “plasmid”, which refers to a circular double stranded-DNA loop into which additional DNA segment may be ligated. In another embodiment, the vector used herein is an expression vector and may be a viral vector, wherein an additional DNA segment can be ligated into the viral genome for expressing the antibodies. The vectors disclosed herein are capable of self-replicating in a host cell into which they have been introduced (for example, a bacterial vector having a bacterial replication origin and an episomal mammalian vector) or may be integrated into the genome of a host cell upon introduction into the host cell, thereby being replicated along with the host genome (e.g., a non-episomal mammalian vector). The host cells may be E. coll cells, yeast cells, insect cells, HEK293 cells, simian COS cells, or Chinese hamster ovary (CHO) cells, or myeloma cells that do not produce immunoglobulin proteins, to synthesize the desired antibodies in the recombinant host cells.

[0061] All degenerate nucleotide sequences are included within the scope of the disclosure as long as the peptide/polypeptide/protein (e.g., the present CDR, VH region or VL region) encoded by the nucleotide sequence maintains the desired activity or function. The term “degenerate nucleotide sequence” denotes a sequence of nucleotides that includes one or more degenerate codons (as compared to a reference polynucleotide molecule that encodes a polypeptide). Degenerate codons contain different tnplets of nucleotides, but encode the same amino acid residue (e.g., GAU and GAC triplets each encode Asp).

[0062] Depending on intended uses, the present antibody or the DNA encoding the antibody may be used to produce chimeric antibodies (e.g., bi-specific antibodies), and/or antibody fragments derived thereof.

[0063] (ii) Method for detecting Porcine Reproductive and Respiratory Syndrome Vims (PRRSV) [0064] According to certain embodiments, the method for detecting PRRSV includes the steps of: (a) preparing a sample; (b) contacting the sample with the present antibody or antigen-binding fragment thereof, and (c) determining the signal from the detection. The sample may be first lysed by a method familiar to a person skilled in the art, for example, freezing and thawing, sonication, pressure, enzyme, detergent, or a combination thereof. The virus in the samples is then detected by the present method or antibody via suitable assay, for instance, western blotting, chemiluminescence microparticle immunoassay (CMIA), chemiluminescence immunoassay (CLIA), lateral flow immunoassay (LFIA) or enzyme-linked immunosorbent assay (ELISA), or using biochip devices (e.g., Bio-FET).

[0065] The following Examples are provided to elucidate certain aspects of the present disclosure and to aid those of skill in the art in practicing this disclosure. These Examples are in no way to be considered to limit the scope of the disclosure in any manner. Without further elaboration, it is believed that one skilled in the art can, based on the description herein, utilize the present disclosure to its fullest extent. All publications cited herein are hereby incorporated by reference in their entirety.

[0066] EXAMPLES

[0067] EXAMPLE 1

[0068] Preparation of the Anti-PRRSV Antibodies

[0069] 1. 1 Antigen preparation [0070] The viral lysate of PRRSV, porcine pseudorabies virus (denoted as S1462), porcine coronavirus (denoted as NTU), and porcine circovirus type 2 (denoted as 110-873 S) are from Dr. Chiou Ming-Tang of National Pingtung University of Science and Technology (NPUST). The unit concentration of viral lysate is determined by Bradford protein assay (BIO-RAD, USA) and diluted by 0.22 micron filtered phosphate-buffered saline (PBS) buffer. The viral lysate is aliquoted and stored at -80°C ready for use.

[0071] 1.2 Immunization

[0072] In order to generate anti-PRRSV antibodies, 6-8 weeks-old female BALB/c mice received an intraperitoneal injection with 100 pg (1 pg/pL) PRRSV viral lysate emulsified with the same volume of complete Freund’s adjuvant (Sigma- Aldrich, USA) respectively.

[0073] Boosting is performed with 100 pg PRRSV viral lysate in incomplete Freund’s adjuvant (Sigma-Aldnch, USA) on days 14, 28, and 42. Before sacrifice, the antibody response is provoked by injection with 50 pg PRRSV viral lysate emulsified with incomplete Freund’s adjuvant twice at three-day intervals before sacrifice.

[0074] 1.3 Hybridoma preparation and antibody purification

[0075] At the end of the immunization schedule, mice spleens are collected immediately and fused with myeloma cells for hybridoma preparation and semi-solid selection subsequently (ClonaCell Hybridoma kit, STEMCELL Technologies, USA). All protocol is followed to the manufacturers’ instructions. Hybridoma colonies are propagated in 96-well microtiter plates (Product No. 3788, Coming, USA) until cells at confluency and their supernatants are harvested to examine antibody response to PRRSV by ELISA test (PRRS X3 Ab Test, IDEXX, USA; described below). Antibodies 477 and 277 with high binding affinity to PRRSV (see below) are selected and purified by protein G Sepharose resin (Cytiva, USA). These purified monoclonal antibodies are dialyzed with PBS buffer to remove glycine and concentrated with Ami con Ultra- 15 centrifugal filter units (10 kDa, Merck Millipore, USA). Monoclonal antibodies are stored at -80 °C for the following experiment.

[0076] 1.4 Determining the binding affinity of anti-PRRSV antibodies

[0077] In order to determine the binding affinity of the instant anti-PRRSV antibodies to PRRSV, an ELISA is performed. First, 96-well microtiter plates are coated with 100 ng of PRRSV viral lysate, which is from Dr. Chiou Ming-Tang of National Pingtung University of Science and Technology (NPUST). Then, 0.5 pg of anti-PRRSV antibody 477 or 277 is added as a pnmary antibody in each well for reacting for 1 hour at room temperature (RT). After 1 hour reaction, unbound antibodies are removed by washing buffer (Tns-buffered saline (TBS) with 0.05% Tween 20). Then, 4000x diluted anti-Mouse IgG-HRP (Jackson ImmunoResearch Laboratory, Code: 515-005-071, USA) is added as a secondary antibody for reacting for 2 hours at RT. After washing with washing buffer (Tris-buffered saline (TBS) with 0.05% Tween 20), the optical density (OD) value is evaluated by measuring the absorbance at 450 nm wavelength (EZ Read 400 Microplate Reader, Biochrom, USA). In the results (not shown), anti-PRRSV antibodies 477 and 277 have higher OD450 values, indicating that antibodies 477 and 277 have high binding affinity to PRRSV, so these two antibodies are selected. Moreover, the anti-PRRSV antibody 277 is used as a comparative example in further examples.

[0078] 1.5 Characterization of two clones of anti-PRRSV antibodies

[0079] According to certain embodiments of the present disclosure, gene sequences of antibody variable regions are resolved from mRNA extracts of anti-PRRSV antibody 477. The gene sequences are then analyzed by IgBlast [IgBlast tool provided by the National Institutes of Health (NIH) (nih.gov)]. After the CDR information is obtained, the polynucleotide sequence (denoted as a DNA sequence) is translated into a polypeptide sequence (denoted as an amino acid sequence) by ExPASy Translate (a tool for translating a nucleotide sequence to a protein sequence, provided by the Swiss Institute of Bioinformatics (SIB)). The polynucleotide sequence (denoted as a DNA sequence) of the 477 VH domain (SEQ ID NO: 8) is translated into the polypeptide sequence (denoted as an amino acid sequence) as the SEQ ID NO: 6, and three CDR sequences of which are the SEQ ID NO: 1 (CDR-H1), SEQ ID NO: 2 (CDR-H2), and SEQ ID NO: 3 (CDR-H3). The polynucleotide sequence (denoted as a DNA sequence) of the 477 VL domain (SEQ ID NO: 9) is translated into the polypeptide sequence (demoted as an amino acid sequence) as the SEQ ID NO: 7, and three CDR sequences of which are the SEQ ID NO: 4 (CDR-L1), SEQ ID NO: 5 (CDR-L3), and CDR-L2 containing a sequence of Leu- Ala-Ser.

[0080] EXAMPLE 2 [0081] The Limit of Quantification for the Anti-PRRSV Antibody

[0082] In order to determine the smallest amount or the lowest concentration of PRRSV that is possible to be quantified with suitable accuracy and precision by the instant anti-PRRSV antibodies 477 and 277, the limit of quantification is confirmed as follows.

[0083] The lowest concentration of PRRSV which can be recognized by the anti-PRRSV antibodies 477 and 277 through an ELISA test is examined. First, the 96-well microtiter plates are respectively coated with 0.78-100 ng of PRRSV viral lysate. Then, 1 pg of the indicated anti-PRRSV antibody is added as a primary antibody in each well for reacting for 1 hour at RT. After removing unbound antibodies by using washing buffer, 2500x diluted anti-Mouse IgG-HRP is added as a secondary' antibody in each well for reacting for 2 hours at RT. After washing with washing buffer, TMB is added and incubated at RT for 30 mins. The OD value at 450 nm is evaluated by an EZ Read 400 Microplate Reader.

[0084] The result for determination of limit of quantification of antibodies 477 and 277 against PRRSV is presented in Table 1. The OD450 values are shown in Table 1, and the background values herein are around 0.15-0.2. As shown in Table 1, the concentration of 477 for the examination is 1.0 pg, and the concentration of 277 for the examination is 1.0. According to the result for determination of limit of quantification of 477 and 277, both 477 and 277 have the ability to detect 0.78-100 ng of PRRSV viral lysate. The lowest concentration of PRRSV which can be recognized by both of the anti-PRRSV antibodies 477 and 277 through the ELISA test is at least 0.78 ng

[0085] Table 1. Results for determination of limit of quantification of each clone of anti-PRRSV antibody against PRRSV by ELISA.

[0086] EXAMPLE 3

[0087] Cross-Reactivity of the Anti-PRRSV Antibody

[0088] Test 1

[0089] In order to confirm specificity of the anti-PRRSV antibodies 477 and 277, the cross-reactivity of the antibodies 477 and 277 against PRRSV viral lysate and lysate of other viruses through an ELISA test is examined. First, 96-well microtiter plates are coated with PRRSV viral lysate (denoted as PRRSV), porcine coronavirus (denoted as NTU), and lysate of pseudorabies virus (denoted as SI 462). Then, 1 :4000 diluted, purified anti-PRRSV antibodies 477 and 277 (with the original concentration of 0.8-1 mg/mL) are added as a primary antibody in each well for reacting for 2 hours at 4°C

[0090] After removing unbound antibodies, 1 :5000 diluted, Peroxidase AffiniPure Goat Anti-Mouse IgG, light chain specific (Code: 1 15-035-174) is added as a secondary antibody for reacting for 2 hours at 4°C. After washing with washing buffer, TMB is added and incubated. The OD450 values are recorded using an EZ Read 400 Microplate Reader. Each viral lysate is tested for two separated repeats which are marked as Group 1 and Group 2, respectively. The result of OD450 values in Test 1 is presented in Table 2 below.

[0091] Test 2

[0092] In order to determine the cross-reactivity of antibodies 477 and 277 against PRRSV viral lysate and lysate of other viruses, an ELISA is performed. First, 96-well microtiter plates are coated with PRRSV viral lysate (denoted as PRRSV), lysate of porcine circovirus type 2 (denoted as 110-873S), and porcine coronavirus (denoted as NTU). Then, 1:4000 diluted, purified anti-PRRSV antibodies 477 and 277 (with the original concentration of 0.8-1.0 mg/mL) are added as a primary antibody in each well for reacting for 2 hours at 4°C.

[0093] After removing unbound antibodies, 1 :2000 diluted in PBS, Peroxidase AffiniPure Goat Anti-Mouse IgG, light chain specific (Code: 115-035-174) is added as a secondary antibody for reacting for 2 hours at 4°C. After washing with washing buffer, TMB is added and incubated. The OD450 values are recorded using an EZ Read 400 Microplate Reader. The result of OD450 values in Test 2 is presented in Table 3 below.

[0094] As shown in Table 2 and Table 3, both the antibody 277 and the antibody 477 show higher OD450 values against PRRSV than that against other viruses, indicating that the antibodies 477 and 277 have the ability to differentiate PRRSV from other viruses.

[0095] Table 3. Result for determination of cross-reactivity of antibodies 477 and 277 against PRRSV viral lysate and lysate of pseudorabies virus (denoted as SI 462) by ELISA.

[0096] Table 4. Results for determination of cross-reactivity of antibodies 477 and 277 against PRRSV viral lysate, lysate of porcine circovirus type 2 (denoted as 110-873S), and porcine coronavirus (denoted as NTU) by ELISA.

[0097] EXAMPLE 4

[0098] Detecting PRRSV by the Anti-PRRSV Antibody Immobilized on a Biosensor Field-Effect Transistor (Bio-FET).

[0099] A Bio-FET has a transistor region and a detecting region, in which the detecting region further includes a detecting surface. In the example of the present disclosure, the detecting surface may be functionalized with the antibody or antigen-bindmg fragment thereof binding to Porcine Reproductive and Respiratory Syndrome Vims (PRRSV). More specifically, in this example, the anti-PRRSV antibodies 477 and 277 are able to be applied on a Bio-FET for detecting PRRSV in a sample. The following examples determine the cross-reactivity (e.g., specificity) and sensitivity of the anti-PRRSV antibodies 477 and 277 by using Bio-FET.

[0100] The steps of coating the anti-PRRSV antibody 477 or 277 on the Bio-FET are shown as follows:

[0101] 1. Antibody immobilization a. Preparing 50 pL of 100 ng/mL anti-PRRSV antibody 477 or 277 solutions in 10 mM Bis-tris propane (BTP) buffer. b. The surface of the Bio-FET is submerged in the 100 ng/mL anti-PRRSV antibody 477 or 277 solutions overnight at 4°C under a condition of 90% relative humidity.

[0102] 2. Blocking by BSA a. The Bio-FET is then rinsed with 10 mM BTP buffer three times. b. The Bio-FET is submerged in 1% Bovine serum albumin (BSA) prepared with pH7, IxPBS buffer for 30 minutes at 37°C. c. The Bio-FET is rinsed with 10 mM BTP buffer three times, followed by two rinses of deionized (DI) water, and blown dry. Then the Bio-FET is ready for use.

[0103] The steps of using the Bio-FET immobilized with the anti-PRRSV antibody 477 or 277 to detect samples are shown as follow: a. First, 100 pL of 10 mM, pH 7 BTP buffer is loaded by a pipette into the polydimethylsiloxane (PDMS) well on the Bio-FET. Then, 10 minutes are given to settle the system before the drain cunent - gate voltage (ID-VG) response is measured. Moreover, only after three successive overlapping ID-VG curves are obtained is the system deemed stable, and the last ID-VG curve can be called the baseline for the next steps in biosensing. b. The BTP buffer from the well is removed. c. 100 pL of the sample is loaded into the well and allowed to hybridize. More specifically, the sample may contain coronavirus, pseudorabies virus or PRRSV. Furthermore, the sample is starting with the lowest concentration to higher concentrations. d. After 10 minutes, the sample is removed, and the well is rinsed with 100 pL of wash buffer (10 mM BTP with 0.05% Tween-20) with a pipette five times. e. Next, the well is rinsed with 100 pL of 10 mM, pH 7 BTP buffer with a pipette five times to remove any unspecific binding. f. A fresh 100 pL of 10 mM, pH 7 BTP buffer is loaded into the well after rinsing. After 10 minutes for the system to settle, the ID-VG response is measured.

[0104] 4.1. The Sensitivity of the Anti-PRRSV Antibody 477 and 277 Immobilized on a

Bio-FET

[0105] The sensitivity of the antibodies 477 and 277 immobilized on Bio-FET are determined using the PRRSV viral lysate (denoted as 763-P8) with different dilution ratios, including 10' ³ , 10' ⁶ , 10' ⁹ , and 10' ¹² dilution, as testing samples. Moreover, pseudorabies virus (denoted as S1462-P7-PRV) with IO" ⁶ dilution is used as a negative control. When the antibody is able to detect the lower concentration, the antibody has the higher sensitivity. When the target biomolecule (i.e., PRRSV) is bonded to the immobilized antibodies 477 or 277, the electric signal of the Bio-FET (represented as threshold voltage differences in the examples) would increase, and thus, in general, the higher the electric signal increase, the more of the biomolecule that is bound.

[0106] The result of the sensitivity of antibody 477 to PRRSV (denoted as 763-P8) is shown in FIG. I A. The sample is PRRSV (denoted as 763-P8) with different dilution ratios, including 10' ³ , 10' ⁶ , 10' ⁹ , and 10' ¹² dilutions. Moreover, pseudorabies virus (denoted as S 1462-P7-PRV) with 10' ⁶ dilution is used as a negative control. As shown in FIG. 1A, electric signals (threshold voltage differences) of the antibody 477 to PRRSV (denoted as 763-P8) with 10' ³ , 10' ⁶ , 1 O' ⁹ , and 10' ¹² are significantly higher than the negative control. Furthermore, the electric signal of the antibody 477 to PRRSV (denoted as 763-P8) with 10' ⁹ dilution is 3 times higher than the negative control, which is the pseudorabies virus (denoted as S1462-P7-PRV) with 10' ⁶ dilution. [0107] The result of the sensitivity of the anti-PRRSV antibody 277 to PRRSV (denoted as 763-P8) is shown in FIG. IB. The samples are PRRSV (denoted as 763-P8) with different dilution ratios, including 10' ³ , 10' ⁶ , 10' ⁹ , and 10' ¹² dilutions. Moreover, pseudorabies virus (denoted as S1462-P7-PRV) with 10' ⁶ dilution is used as a negative control. As shown in FIG. IB, only the electric signals of the anti-PRRSV antibody 277 to PRRSV (denoted as 763-P8) with 10' ³ and 10' ⁶ dilution are significantly higher than the negative control, while the electric signals of the anti-PRRSV antibody 277 to PRRSV (denoted as 763-P8) with 10' ⁹ and 10' ¹² dilution are even significantly lower than the negative control. Furthermore, only when the PRRSV with IO" ³ dilution, the electric signal of the anti-PRRSV antibody 277 to PRRSV (denoted as 763-P8) could be 3 times higher than the negative control, which is the porcine coronavirus (denoted as FCOV-P7) with 10' ⁶ dilution. Therefore, the results indicate that the sensitivity of the antibody 477 on the Bio-FET is better than that of the antibody 277.

[0108] 4.2 The Cross-Reactivity of the Anti-PRRSV Antibody 477 Immobilized on a

Bio-FET

[0109] In order to determine the specificity of the antibody 477 immobilized on Bio-FET, the cross reactivity of the antibody 477 immobilized on Bio-FET against PRRSV (denoted as 763-P8) and other viruses, including pseudorabies virus (denoted as S1462-P7-PRV), porcine coronavirus

(denoted as FCOV-P7), and porcine circovirus type 2 (denoted as 110-873S) are examined. When the antibody shows lower cross-reactivity, the antibody has higher specificity.

[0110] The result of the cross-reactivity' of the anti-PRRSV antibody 477 to PRRSV (denoted as 763-P8), pseudorabies virus (denoted as S1462-P7-PRV), porcine coronavirus (denoted as FCOV-P7), and porcine circovirus type 2 (denoted as 110-873S) is shown in FIG. 2. Those samples are used with 10" ³ or 10' ⁶ dilution. As shown in FIG. 2, the electric signals of the anti-PRRSV antibody 477 to PRRSV (denoted as 763-P8) are significantly higher than the electric signals to pseudorabies virus (denoted as S1462-P7-PRV), porcine coronavirus (denoted as FCOV-P7), and porcine circovirus type 2 (denoted as 110-873S) with IO" ⁶ dilution.

[0111] As aforementioned, when being applied on the ELISA, the antibodies 477 and 277 both show high specificity and sensitivity to PRRSV. However, when being applied on the Bio-FET, the antibody 477 shows high sensitivity to PRRSV while the antibody 277 does not, which indicates that the antibody 477 could not only be applied on the ELISA, but also be a good candidate for Bio-FET field to detect PRRSV.

[0112] Application

[0113] For the application of detection PRRSV, the anti-PRRSV antibodies 477 and 277 may be used to detect an animal (e.g., pig) infected with PRRSV by using assays such as western blotting, CMIA, CLIA, LFIA, ELISA, and may be used to prepare a composition for detecting PRRSV in the animal or a sample from the animal, such as for use in biochip devices (e g.,

Bio-FET) or a detection kit for western blotting, CMIA, CLIA, LFIA, ELISA, or the biochip devices.